AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at Shore Capital in a note issued to investors on Thursday, Marketbeat Ratings reports.
A number of other analysts have also recently weighed in on AZN. Barclays reiterated an “overweight” rating and set a £125 ($161.67) price target on shares of AstraZeneca in a research note on Monday, April 8th. Jefferies Financial Group upped their price objective on shares of AstraZeneca from GBX 71 ($0.92) to GBX 74 ($0.96) and gave the stock a “hold” rating in a research report on Tuesday, July 2nd. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, June 4th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £110 ($142.27) price objective on shares of AstraZeneca in a research report on Tuesday, June 18th. Finally, Berenberg Bank upped their price objective on shares of AstraZeneca from £130 ($168.13) to £150 ($194.00) and gave the stock a “buy” rating in a research report on Friday, June 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average price target of £105.53 ($136.49).
Check Out Our Latest Analysis on AZN
AstraZeneca Stock Up 1.0 %
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
- Five stocks we like better than AstraZeneca
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Short Selling: How to Short a Stock
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.